Abstracts Clinical Lymphoma, Myeloma & Leukemia September 2023 S352 up duration was 12 years after allo-HCT; 19 patients died. Median OS was 15.0 months after transplantation (95%CI: 5.1-71.1) and 19.7 months after diagnosis (95%CI: 6.2-38.7). OS at 100 days and at 1, 3, and 5 years post-HCT was 78%, 52%, 35%, and 35%, respectively. 10 patients (37%) relapsed at a median of 9 months after allo-HCT. Median RFS was 10.7 months (95%CI: 3.4-15.7), with 100-day, 1-, 3-, and 5-year RFS of 74%, 44%, 22%, and 16%. Acute GVHD ≥ grade 3 occurred in 7 patients (26%), and chronic GVHD occurred in 13 (48%). Median GRFS was 5.5 months (95%CI: 3.2-9.5), with 100-day, 1-, 3-, and 5-year GRFS of 67%, 26%, 10%, and 5%. Patients with CMML-MDS had significantly longer OS (median, 8.6 vs 0.9 years; P=0.025), RFS (4.4 vs 0.5 years; P=0.021), and GRFS (9.4 vs 3.4 months; P=0.033), and a lower NRM rate (13% vs 47% at 1 year; P=0.043) than patients with CMML-MPN. High-risk cytogenetics were associated with shorter GRFS compared with intermediate- or low-risk cytogenetics (median, 3.1 vs 6.2 months; P=0.013). Conclusions: Allo-HCT can be curative in CMML, with better outcomes in CMML-MDS than in CMML-MPN. Future studies are needed for transplantation optimization in CMML, especially CMML-MPN. Keywords: chronic myelomonocytic leukemia, secondary AML, allogeneic hematopoietic stem cell transplant MDS-044 Cancer Disparities in Survival of Patients With Hematologic Malignancies in the Context of Social Determinants of Health: A Systematic Review Marisol Miranda-Galvis PhD1, Kellen Tjioe PhD1, Andrew Balas MD, PhD2, Gagan Agrawal PhD2, Jorge Cortes MD1 1Georgia Cancer Center, Augusta, USA. 2Augusta University, Augusta, USA Context: Despite tremendous improvement in the survival expectation of patients with hematologic malignancies in the last years, certain disadvantaged groups experience higher mortality rates. Social determinants of health (SDH) have been reported as relevant factors responsible for the cancer outcomes inequity. Objective: We sought to assess clinical data in the United States regarding the impact of SDH on cancer treatment outcomes, specifically in patients with hematologic malignancies. Design: We performed a comprehensive systematic review using PubMed, Cochrane, EMBASE, Scopus, and Web of Science databases. Our inclusion criteria consisted of observational studies investigating any SDH impact on hematologic malignancy treatment survival. Our outcomes were any cancer treatment survival measures, such as early mortality, disease-free survival, cancer-specific survival, response to therapy, and overall survival. Results: We included data from 41 studies with 390,789 patients that covered the analysis of 134 SDH. The most common SDH explored were healthcare access and quality (54.3%) and economic stability (27.1%); others investigated were education (14.7%) and social and community context (7.8%). We identified strong evidence of 5 variables significantly affecting survival: lack of health insurance coverage or having public insurance; receiving cancer treatment at a nonacademic facility; low household income; low education level; and being unmarried. In contrast, the reports on the effect of distance traveled to the treatment center are contradictory. Other SDH examined were facility volume (n=4), provider expertise (n=2), poverty (n=4), and employment rates (n=2). Nevertheless, it is difficult to draw any conclusion from those last variables due to the limited number of studies that explored them. We also identified gaps in the literature in terms of transportation, debt, language, higher education, hunger, access to a healthy diet, social integration, discrimination, or stress. Conclusions: Our results underscore the complex nature of the social, financial, and healthcare barriers as intercorrelated variables. Therefore, the management of hematologic malignancies needs to concert efforts into incorporating SDH into clinical care, research, and public health policies, identifying and addressing the barriers at a patient-based level to enhance outcome equity. Keywords: hematologic malignancies, social determinants of health, health disparities, health equity, survival MDS-065 Treatment Patterns and Transfusion Outcomes Among Erythropoietin‑Stimulating Agent (ESA)‑Naïve Patients With Lower‑Risk Myelodysplastic Syndromes (LR‑MDS) Receiving Luspatercept in Routine Clinical Practice in the United States (US) Sudipto Mukherjee MD, PhD1, Cherrishe BrownBickerstaff PhD, MPH2, David Huggar PharmD3, Angelica Falkenstein PhD2, Adeola Y. Makinde PhD3, Emily Bland MPH2, JaLyna Laney PhD2, Marné Garretson MPH2, Ali McBride PharmD3 1Cleveland Clinic, Cleveland, OH, USA. 2Cardinal Health Specialty Solutions, Dublin, OH, USA. 3Bristol Myers Squibb, Princeton, NJ, USA Context: Limited real-world data exists evaluating the effectiveness of luspatercept in ESA-naïve patients with LR-MDS. Objective: To describe treatment patterns and transfusion outcomes among ESAnaïve patients with LR-MDS who received luspatercept in routine clinical practice. Methods: This retrospective, observational cohort study used physician-abstracted data from US medical records of adults with LR-MDS (IPSS score Low or Intermediate-1 risk and/ or IPSS-Revised score Very Low, Low, or Intermediate risk) on or after January 1, 2015 who received luspatercept for ≥3 months (excluding <3 months due to death). Physicians were recruited from Cardinal Health Oncology Provider Extended Network. Data were collected between May 31–July 12, 2022. Patients who received any treatment for MDS or luspatercept in a clinical trial were ineligible. This subgroup analysis assessed patients who were ESA-naïve at luspatercept initiation. Transfusion burden (TB) was defined based on the lowest number of red blood cell (RBC) and/ or platelet transfusion sessions (any RBC and/or platelet units received in a single day) during any consecutive ≥8- or 12-week
RkJQdWJsaXNoZXIy MTk3NTQxMg==